Accordingly, we investigated the effects of PLK1 and WEE1 inhibition in BRCA-WT and BRCA-Mut HGSOC models, focusing on DNA repair dependency, cell cycle regulation, and differential drug sensitivity, to identify therapeutic strategies for BRCA-WT and HRP ovarian cancers. This evidence concerns the gene WEE1 and ovarian carcinoma.